July 20, 2024

Inhaled Nitric Oxide Delivery Systems Market Size, Share by 2030

The global inhaled nitric oxide delivery systems market size is expected to be worth around US$ 530.2 million by 2030, according to a new report by Vision Research Reports.

The global inhaled nitric oxide delivery systems market size was valued at US$ 260.5 million in 2020 and is anticipated to grow at a CAGR of 7.9% during forecast period 2021 to 2030.

inhaled nitric oxide delivery systems

 

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38877

Inhaled Nitric Oxide Delivery Systems Market Growth Factors

 A rise in the cases of respiratory failure among neonates, increased pollution levels leading to lung diseases in adults, need for quick treatment response, and reduced complications are the factors driving the adoption of inhaled nitric oxide therapy. The presence of several small-scale manufacturers and research initiatives undertaken by major players to prove treatment efficacy against the SARS-CoV-2 virus further enhances market growth.

Safe and effective treatment regimen, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medications.

Inhaled Nitric Oxide Delivery Systems Market Report Coverage
Report Scope Details
Market Size USD 530.2 million by 2030
Growth Rate CAGR of 7.9% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Type, application, product, end user
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals
By Type Analysis

The pediatric segment accounted for the largest revenue share of 77.6% in 2020. Inhaled nitric oxide is proved to be the most effective in treating neonatal diseases like Hypoxic Respiratory Failure (HRF).

low cost of raw materials, abundant resource availability, and a large consumer base, are also anticipated to boost segment growth. INO delivery devices are priced at USD 1400-1700, which makes it difficult for low-tier end-user settings to adopt such equipment as they focus on minimizing the bills.

By End-user Analysis

The hospitals segment captured the highest revenue share of 87.2% in 2020 owing to the ease of delivery, ability to liquidate for establishing INO delivery device and monitor system, a large number of staff to track device operations, and presence of emergency department.

Mortality rates due to ARFare around 30% in the world. Hence, it is essential to provide these patients with life support and critical care, such as that in hospital ICUs. A rise in the number of hospital admissions is leading to the growth of this segment

By Regional Analysis

North America is expected to be the fastest-growing regional market registering a CAGR of 7.84% during the forecast period. This growth can mainly be attributed to the increasing incidences of neonatal mortality due to the rising cases of HRF.

APAC held the largest revenue share in 2020 and will continue the trend during the forecast period due to the growing pediatric population, a rise in the number of patients suffering from respiratory failure, and the presence of local manufacturers of nitric oxide disposables & systems.

Read also @ E-Clinical Solutions Market Estimated to Cross US$ 22.7 Bn by 2030

Major Key Players Covered in The Inhaled Nitric Oxide Delivery Systems Market Report include
  • Mallinckrodt Pharmaceuticals
  • Getinge
  • Vero Biotech
  • LINDE
  • Beyond Air
  • SLE
  • NU MED
  • Bellerophon Therapeutics
  • Air Liquide Healthcare
  • Circassia Pharmaceuticals
Inhaled Nitric Oxide Delivery Systems Market Segmentation
  • By Type
    • Pediatrics
    • Adult
  • By Application
    • Hypoxic Respiratory Failure (HRF)
    • Acute Hypoxemic Respiratory Failure (AHRF)
    • Others
  • By Product
    • Disposables
    • System
  • By End-user
    • Hospitals
    • Ambulatory Centers
    • Clinics
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Norway
      • Sweden
      • Russia
    • Asia Pacific
      • Japan
      • China
      • India
      • Thailand
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Turkey

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Inhaled Nitric Oxide Delivery Systems Market Snapshot

Chapter 4.  Inhaled Nitric Oxide Delivery Systems Market Variables and Scope

4.1.  Introduction

4.2.  Inhaled Nitric Oxide Delivery Systems Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Product Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Inhaled Nitric Oxide Delivery Systems Market Dynamics Analysis and Trends

5.1.  Inhaled Nitric Oxide Delivery Systems Market Dynamics

5.1.1.    Inhaled Nitric Oxide Delivery Systems Market Drivers

5.1.2.    Inhaled Nitric Oxide Delivery Systems Market  Restraints

5.1.3.    Inhaled Nitric Oxide Delivery Systems Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Inhaled Nitric Oxide Delivery Systems Market, By Type

7.1.  Inhaled Nitric Oxide Delivery Systems Market, by Type, 2021-2030

7.1.1.    Pediatrics

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Adult

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Inhaled Nitric Oxide Delivery Systems Market, By Application

8.1.  Inhaled Nitric Oxide Delivery Systems Market, by Application, 2021-2030

8.1.1.    Hypoxic Respiratory Failure (HRF)

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Acute Hypoxemic Respiratory Failure (AHRF)

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Others

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Inhaled Nitric Oxide Delivery Systems Market, By Product

9.1.  Inhaled Nitric Oxide Delivery Systems Market, by Product, 2021-2030

9.1.1.    Disposables

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    System

9.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Inhaled Nitric Oxide Delivery Systems Market, By End-user

10.1.        Inhaled Nitric Oxide Delivery Systems Market, by End-user, 2021-2030

10.1.1.  Hospitals

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Ambulatory Centers

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Clinics

10.1.3.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Inhaled Nitric Oxide Delivery Systems Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Type (2017-2030)

11.1.2.  Market Revenue and Forecast, by Application (2017-2030)

11.1.3.  Market Revenue and Forecast, by Product (2017-2030)

11.1.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Type (2017-2030)

11.2.2.  Market Revenue and Forecast, by Application (2017-2030)

11.2.3.  Market Revenue and Forecast, by Product (2017-2030)

11.2.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by Product (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Type (2017-2030)

11.3.2.  Market Revenue and Forecast, by Application (2017-2030)

11.3.3.  Market Revenue and Forecast, by Product (2017-2030)

11.3.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by Product (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Type (2017-2030)

11.4.2.  Market Revenue and Forecast, by Application (2017-2030)

11.4.3.  Market Revenue and Forecast, by Product (2017-2030)

11.4.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by Product (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Type (2017-2030)

11.5.2.  Market Revenue and Forecast, by Application (2017-2030)

11.5.3.  Market Revenue and Forecast, by Product (2017-2030)

11.5.4.  Market Revenue and Forecast, by End-user (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by Product (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by Product (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12.  Company Profiles

12.1.              Mallinckrodt Pharmaceuticals

12.1.1.  Company Overview

12.1.2.  Type Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Getinge

12.2.1.  Company Overview

12.2.2.  Type Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Vero Biotech

12.3.1.  Company Overview

12.3.2.  Type Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              LINDE

12.4.1.  Company Overview

12.4.2.  Type Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Beyond Air

12.5.1.  Company Overview

12.5.2.  Type Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              SLE

12.6.1.  Company Overview

12.6.2.  Type Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              NU MED

12.7.1.  Company Overview

12.7.2.  Type Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Bellerophon Therapeutics

12.8.1.  Company Overview

12.8.2.  Type Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Air Liquide Healthcare

12.9.1.  Company Overview

12.9.2.  Type Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Circassia Pharmaceuticals

12.10.1.               Company Overview

12.10.2.               Type Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38877

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Leave a Reply

Your email address will not be published. Required fields are marked *